Professor Daniel Galvao
Edith Cowan University's (ECU's) Director of the Exercise Medicine Research Institute, Professor Daniel Galvão has been appointed National Chair of the Research Advisory Committee for the Prostate Cancer Foundation of Australia (PCFA).
The Research Advisory Committee comprises a group of researchers, clinicians and people with lived experience who advise on the strategic direction for the PCFA's Research Program, including identifying areas of prostate cancer research which are under-investigated and developing strategies to correct that imbalance.
"I am delighted to be appointed Chair of the Research Advisory Committee and to contribute to the important work that PCFA undertakes to improve treatment outcomes and enhance quality of life for people affected by prostate cancer," Professor Galvão said.
"The Committee comprises some of the most respected clinicians and scientists in Australia, as well as individuals with lived experience of the impact of prostate cancer. The opportunity to serve as Chair and to help facilitate discussions on this diagnosis is a great honour."
Prostate cancer is the most commonly diagnosed cancer in Australia, and the most commonly diagnosed cancer among Australian men. The PFCA estimates that around 79 Australian men are diagnosed each day with prostate cancer, and around 11 Australian men will die each day from the disease.
The estimated risk of a man being diagnosed with prostate cancer in his lifetime is one in five, and the estimated risk of a man dying from prostate cancer in his lifetime is one in 23.
The PFCA is dedicated to reducing the impact of prostate cancer on Australian men and their families through promoting and funding research, awareness, education and advocacy campaigns, and supporting those impacted by prostate cancer through evidence-based information and resources, support groups and specialist nurses.
"Professor Galvão's appointment as Chair of PCFA's Research Advisory Committee reflects both his outstanding leadership in exercise oncology and his deep commitment to improving outcomes for men affected by prostate cancer. We are delighted to have him guiding the strategic direction of our research program at such a critical time," PCFA CEO Anne Savage said.
"As we look to the future, the role of PCFA's Research Advisory Committee has never been more important for Australian men and families impacted by prostate cancer. Professor Galvão's appointment will strengthen our ability to identify research gaps, support world-class science, and ensure better outcomes for all Australians impacted by prostate cancer.
"We're looking forward to his continuing engagement in our mission and vision for zero deaths."
